Prostate cancer is the second leading cause of cancer deaths among men in the United States. African- American men are disproportionately impacted by prostate cancer and exhibit the highest incidence and mortality rate in the world. The underlying reasons for significant prostate cancer health disparities in African- American men are not clearly understood and may include both biological and socio-economic factors. The RCMl program has helped Clark Atlanta University (CAU) to establish the Center for Cancer Research and Therapeutic Development (CCRTD), a premier research program in prostate cancer. CCRTD focuses on understanding prostate cancer health disparities and has successfully trained the next generation of minority scientists in the area of prostate cancer and developed a community-based educational and research program focusing on the early detection and treatment of prostate cancer. In this RCMl renewal application, we propose to enhance, improve and manage our research programs to increase efficient use of technologies, increase research capacity and competitiveness and expand our network through collaborations and partnerships with researchers, research institutes and community organizations. We propose the following specific aims to achieve our goals: 1) To recruit and support additional scientists to build a competitive basic and translational research center focused on prostate cancer health disparities and 2) To maintain and expand the existing research infrastructure within CCRTD. To achieve the specific aims, we plan to focus on two primary activities: a) Administrative Core Activity and b) Technologies and Resources for Core Laboratories Activity. Under the Administrative Core Activity, our key focus areas will be i) Collaborations and Partnerships;ii) Professional Development Activities;iii) Evaluation Plan;iv) Recruitment and Hiring of Additional Faculty Investigators/Research Staff;and v) Pilot Project Program. RCMl funding is vital for the continued development of biomedical research infrastructure at CAU in general and to assist CCRTD in expanding its focus on prostate cancer, a disease that disproportionately impacts African Americans.
Prostate cancer affects the African-American community disproportionately. There is an increased incidence/mortality rate for African-American men however the reason for this is unknown. The Center for Cancer Research and Therapeutic Development is committed to focus on the impact of this health disparity within the African-American community.
|Brown, Shanora G; Knowell, Ashley E; Hunt, Aisha et al. (2015) Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 75:266-79|
|Patel, Divya; Morton, Derrick J; Carey, Jason et al. (2015) Inhibitor of differentiation 4 (ID4): From development to cancer. Biochim Biophys Acta 1855:92-103|
|Smith, Basil; Randle, Diandra; Mezencev, Roman et al. (2014) Camalexin-induced apoptosis in prostate cancer cells involves alterations of expression and activity of lysosomal protease cathepsin D. Molecules 19:3988-4005|
|Burton, Liza J; Barnett, Petrina; Smith, Basil et al. (2014) Muscadine grape skin extract reverts snail-mediated epithelial mesenchymal transition via superoxide species in human prostate cancer cells. BMC Complement Altern Med 14:97|
|Powell, Joann B; Ghotbaddini, Maryam (2014) Cancer-promoting and Inhibiting Effects of Dietary Compounds: Role of the Aryl Hydrocarbon Receptor (AhR). Biochem Pharmacol (Los Angel) 3:|
|Richmond, Oliver; Ghotbaddini, Maryam; Allen, Cidney et al. (2014) The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells. PLoS One 9:e95058|
|Vo, Baohan T; Morton Jr, Derrick; Komaragiri, Shravan et al. (2013) TGF-* effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154:1768-79|
|Guo, Shanchun; Zou, Jin; Wang, Guangdi (2013) Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des Devel Ther 7:1259-71|
|Tran, Cindy; Richmond, Oliver; Aaron, Latayia et al. (2013) Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells. Biochem Pharmacol 85:753-62|
|Gryder, Berkley E; Akbashev, Michelle J; Rood, Michael K et al. (2013) Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem Biol 8:2550-60|